Kapadi

𝗬𝗼𝘂𝗿 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘀𝗵𝗼𝘂𝗹𝗱 𝗻𝗼𝘁 𝗻𝗲𝗲𝗱 𝗮 𝗹𝗮𝗿𝗴𝗲𝗿 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝘁𝗲𝗮𝗺 𝗷𝘂𝘀𝘁 𝘁𝗼 𝗺𝗮𝗻𝗮𝗴𝗲 𝘁𝗵𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 running its oncology trial. Humaneva Oncology connects oncology-specialized sites, purpose-built CRO delivery, and patient intelligence within 𝗼𝗻𝗲 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗲𝘅𝗲𝗰𝘂𝘁𝗶𝗼𝗻 𝗺𝗼𝗱𝗲𝗹. Fewer handoffs. Clearer visibility. One partner accountable for delivery. Give your science an operating model built to keep pace. Discover Humaneva Oncology: 🔗 https://lnkd.in/ezx-egGV #HumanevaOncology #Kapadi #Pratia #OncologyTrials #ClinicalDevelopment #Biotech #ClinicalResearch

Oncology trials are becoming increasingly difficult to execute. The science has evolved. The operating model hasn't. Humaneva Oncology brings together @Kapadi and @Pratia into one integrated model designed to reduce fragmentation and improve accountability across oncology trials. One partner. One system. One accountable outcome. Learn more: 🔗 www.kapadi.com/oncology

In a fast-moving oncology trial, data that is eventually clean may still arrive too late to support the decision. Medical and operational decisions may need to be made within days. A traditional sequence of site entry, source data verification, and subsequent data management review can create a lag between what is happening in the trial and what the study team can confidently see. Modern data strategy must be designed around the decisions the study needs to make. At Kapadi, our clinical data management and risk-based quality experts treat data as a critical trial deliverable from the outset. This includes: • Identifying critical data and processes early • Designing focused and purposeful EDC systems • Targeting data review across functional areas • Harmonizing and consolidating information • Tracking patient journeys and protecting critical endpoints 𝗦𝗽𝗲𝗲𝗱 𝗮𝗻𝗱 𝗶𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆 𝘀𝗵𝗼𝘂𝗹𝗱 𝗻𝗼𝘁 𝗰𝗼𝗺𝗽𝗲𝘁𝗲 𝘄𝗶𝘁𝗵 𝗼𝗻𝗲 𝗮𝗻𝗼𝘁𝗵𝗲𝗿. 𝗪𝗵𝗲𝗻 𝗱𝗮𝘁𝗮 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗶𝘀 𝗯𝘂𝗶𝗹𝘁 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗺𝗼𝗱𝗲𝗹, 𝘁𝗲𝗮𝗺𝘀 𝗰𝗮𝗻 𝗴𝗮𝗶𝗻 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 𝘃𝗶𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝘄𝗵𝗶𝗹𝗲 𝗺𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗱 𝗳𝗼𝗿 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀. Melanie Marshall discusses this approach in the attached excerpt from our May webinar, “Reduce Delays from Operational Gaps in Oncology Trials.” Watch the full webinar: https://lnkd.in/etAaRMV9 #ClinicalDataManagement #RBQM #OncologyClinicalTrials #DataQuality

Modern oncology trials are not simply becoming more complex. They are becoming more volatile. Protocol amendments, multiple vendors, activation delays, narrow molecular eligibility criteria, competing studies, biomarker attrition, supply chain dependencies, and long-term follow-up obligations can all affect delivery. The real challenge is that these pressures do not occur independently. They interact. A change in eligibility may affect recruitment. Recruitment uncertainty changes timelines and resource requirements. Supply constraints can disrupt treatment schedules. Long-term follow-up adds obligations that extend well beyond the initial study period. Historical assumptions and static forecasts are no longer enough. At Kapadi, we approach complexity as an interconnected system. Our teams combine medical, regulatory, operational, data, and site perspectives to identify dependencies, stress-test assumptions, monitor leading indicators, and adapt plans before emerging variance becomes a material delay. 𝗦𝗽𝗼𝗻𝘀𝗼𝗿𝘀 𝗱𝗼 𝗻𝗼𝘁 𝗻𝗲𝗲𝗱 𝗺𝗼𝗿𝗲 𝘀𝘁𝗮𝘁𝘂𝘀 𝗿𝗲𝗽𝗼𝗿𝘁𝗶𝗻𝗴. 𝗧𝗵𝗲𝘆 𝗻𝗲𝗲𝗱 𝗮𝗻 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗺𝗼𝗱𝗲𝗹 𝗿𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝘁 𝗲𝗻𝗼𝘂𝗴𝗵 𝘁𝗼 𝗮𝗯𝘀𝗼𝗿𝗯 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗼𝘂𝘀 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗮𝗻𝗱 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗵𝗮𝗻𝗴𝗲. Dr. Brandon Fletcher explores this challenge in the attached excerpt from our May webinar, “Reduce Delays from Operational Gaps in Oncology Trials.” Watch the full webinar here: https://hubs.li/Q04sQrbX0 #Oncology #ClinicalOperations #ClinicalTrials #TrialExecution

Oncology trials are not being strained by one operational problem. They are being strained by multiple pressures compounding at the same time. Phase III trials now generate an average of 3.6 million data points. More than 90% of oncology protocols undergo amendments. Biomarker-defined cohorts narrow the available patient pool, while testing delays can consume critical screening windows. Sites face redundant feasibility activities, workforce shortages, and growing regulatory and administrative demands. Each challenge may appear manageable in isolation. Together, they create a system under strain. At Kapadi, this is why we do not treat protocol design, feasibility, biomarker strategy, enrollment, data quality, site readiness, regulatory planning, and operational forecasting as disconnected workstreams. Our oncology experts connect these elements early, helping sponsors translate scientific ambition into trials that are executable for sites, accessible to patients, and capable of producing high-integrity, decision-ready data. The answer to increasing complexity is not simply more activity. It is better integration, earlier risk identification, and an operating model designed around how modern oncology trials actually work. 𝗗𝗿. 𝐁𝐫𝐚𝐧𝐝𝐨𝐧 𝐅𝐥𝐞𝐭𝐜𝐡𝐞𝐫 𝗲𝘅𝗮𝗺𝗶𝗻𝗲𝘀 𝘁𝗵𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗯𝗲𝗵𝗶𝗻𝗱 𝘁𝗵𝗲𝘀𝗲 𝗽𝗿𝗲𝘀𝘀𝘂𝗿𝗲𝘀 𝗶𝗻 𝗼𝘂𝗿 𝗻𝗲𝘄 𝘄𝗵𝗶𝘁𝗲 𝗽𝗮𝗽𝗲𝗿, “𝗧𝗵𝗲 𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗕𝘂𝗿𝗱𝗲𝗻 𝗼𝗳 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗔 𝗦𝘆𝘀𝘁𝗲𝗺 𝗨𝗻𝗱𝗲𝗿 𝗦𝘁𝗿𝗮𝗶𝗻.” Read the full white paper here https://lnkd.in/eKRnnFzi #OncologyClinicalTrials #ClinicalDevelopment #TrialOperations #Biotech #WhitePaper

A promising oncology trial can lose valuable time long before the first patient is enrolled. Complex eligibility criteria, inconsistent genomic testing, fragmented referral pathways and disconnected data systems can create operational gaps across sponsors, CROs and sites. The result is slower screening, unpredictable enrollment and avoidable pressure on study timelines. In our on-demand webinar, Kapadi experts Brandon Fletcher and Melanie Marshalll join other industry leaders to discuss why scientific innovation must be supported by an operating model capable of keeping pace. Watch the snippet below, then explore the full webinar for their insights into how stronger coordination, site readiness and data connectivity can support faster, more reliable oncology trial execution. Watch the full video here: https://hubs.li/Q04s62cV0 #Webinar #WebinarOnDemand #Pratia #Kapadi #Humaneva #HumanevaGroup #ClinicalTrials #Oncology #ClinicalResearch #PatientRecruitment #PrecisionMedicine #TrialOperations